Our top pick for
Neuronetics Inc is a diagnostics & research business based in the US. Neuronetics shares (STIM) are listed on the NASDAQ and all prices are listed in US Dollars. Neuronetics employs 161 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$4.94|
|52-week range||$4.78 - $22.43|
|50-day moving average||$6.82|
|200-day moving average||$11.51|
|Wall St. target price||$17.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.03|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-22.93%|
|1 month (2021-09-16)||-24.00%|
|3 months (2021-07-16)||-63.68%|
|6 months (2021-04-16)||-57.04%|
|1 year (2020-10-16)||-20.96%|
|2 years (2019-10-16)||-44.24%|
|3 years (2018-10-16)||24.19|
|5 years (2016-10-12)||N/A|
|Revenue TTM||$54.5 million|
|Gross profit TTM||$37.7 million|
|Return on assets TTM||-9.18%|
|Return on equity TTM||-35.51%|
|Market capitalisation||$168.7 million|
TTM: trailing 12 months
There are currently 1.9 million Neuronetics shares held short by investors – that's known as Neuronetics's "short interest". This figure is 11.9% down from 2.1 million last month.
There are a few different ways that this level of interest in shorting Neuronetics shares can be evaluated.
Neuronetics's "short interest ratio" (SIR) is the quantity of Neuronetics shares currently shorted divided by the average quantity of Neuronetics shares traded daily (recently around 472046.96969697). Neuronetics's SIR currently stands at 3.96. In other words for every 100,000 Neuronetics shares traded daily on the market, roughly 3960 shares are currently held short.
However Neuronetics's short interest can also be evaluated against the total number of Neuronetics shares, or, against the total number of tradable Neuronetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neuronetics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Neuronetics shares in existence, roughly 70 shares are currently held short) or 0.0778% of the tradable shares (for every 100,000 tradable Neuronetics shares, roughly 78 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neuronetics.
Find out more about how you can short Neuronetics stock.
We're not expecting Neuronetics to pay a dividend over the next 12 months.
Over the last 12 months, Neuronetics's shares have ranged in value from as little as $4.78 up to $22.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neuronetics's is 2.4929. This would suggest that Neuronetics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Neuronetics, Inc. , a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.